$NGM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NGM BIOPHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NGM BIOPHARMACEUTICALS INC. Get notifications about new insider transactions in NGM BIOPHARMACEUTICALS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 10 2021 | NGM | NGM BIOPHARMACEUTI ... | LESCHLY MARK | Director | Option Exercise | A | 17.24 | 19,619 | 338,232 | 19,619 | |
| Jun 10 2021 | NGM | NGM BIOPHARMACEUTI ... | Ho Carole | Director | Option Exercise | A | 17.24 | 19,619 | 338,232 | 19,619 | |
| May 04 2021 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 27.62 | 25,000 | 690,500 | 920,005 | 945 K to 920 K (-2.65 %) |
| Apr 13 2021 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 24.65 | 25,000 | 616,250 | 945,005 | 970 K to 945 K (-2.58 %) |
| Mar 18 2021 | NGM | NGM BIOPHARMACEUTI ... | Pierce Valerie L | SVP, GC & CCO | Option Exercise | A | 31.93 | 100,000 | 3,193,000 | 100,000 | |
| Mar 18 2021 | NGM | NGM BIOPHARMACEUTI ... | Lieu Hsiao D | SVP, Chief Medical ... | Option Exercise | A | 31.93 | 100,000 | 3,193,000 | 100,000 | |
| Mar 18 2021 | NGM | NGM BIOPHARMACEUTI ... | Nolan Mangini Siobhan | Chief Financial Off ... | Option Exercise | A | 31.93 | 50,000 | 1,596,500 | 50,000 | |
| Mar 18 2021 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Option Exercise | A | 31.93 | 175,000 | 5,587,750 | 175,000 | |
| Mar 18 2021 | NGM | NGM BIOPHARMACEUTI ... | WOODHOUSE DAVID J | Chief Executive Off ... | Option Exercise | A | 31.93 | 450,000 | 14,368,500 | 450,000 | |
| Mar 18 2021 | NGM | NGM BIOPHARMACEUTI ... | RIEFLIN WILLIAM JL | Executive Chairman | Option Exercise | A | 31.93 | 80,000 | 2,554,400 | 80,000 | |
| Mar 02 2021 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 26.66 | 25,000 | 666,500 | 970,005 | 995 K to 970 K (-2.51 %) |
| Feb 03 2021 | NGM | NGM BIOPHARMACEUTI ... | Nolan Mangini Siobhan | Chief Financial Off ... | Option Exercise | A | 18.88 | 300,000 | 5,664,000 | 300,000 | |
| Feb 03 2021 | NGM | NGM BIOPHARMACEUTI ... | Nolan Mangini Siobhan | Chief Financial Off ... | Option Exercise | A | 18.88 | 300,000 | 5,664,000 | 300,000 | |
| Jan 06 2021 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Option Exercise | M | 0.60 | 150,000 | 90,000 | 0 | |
| Jan 06 2021 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Buy | M | 0.60 | 150,000 | 90,000 | 1,020,005 | 870 K to 1 M (+17.24 %) |
| Jan 06 2021 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 30.26 | 370 | 11,196 | 870,005 | 870.4 K to 870 K (-0.04 %) |
| Jan 06 2021 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 29.27 | 24,630 | 720,920 | 870,375 | 895 K to 870.4 K (-2.75 %) |
| Dec 16 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 28.89 | 3,145 | 90,859 | 895,005 | 898.2 K to 895 K (-0.35 %) |
| Dec 16 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 28.19 | 10,729 | 302,451 | 898,150 | 908.9 K to 898.2 K (-1.18 %) |
| Dec 16 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 27.59 | 11,126 | 306,966 | 908,879 | 920 K to 908.9 K (-1.21 %) |
| Nov 04 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 17.70 | 25,000 | 442,500 | 920,005 | 945 K to 920 K (-2.65 %) |
| Oct 13 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 17.02 | 25,000 | 425,500 | 945,005 | 970 K to 945 K (-2.58 %) |
| Sep 03 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.67 | 27,595 | 487,604 | 1,827,025 | 1.8 M to 1.8 M (+1.53 %) |
| Sep 03 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.64 | 36,494 | 643,754 | 1,799,430 | 1.8 M to 1.8 M (+2.07 %) |
| Sep 03 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.67 | 27,595 | 487,604 | 1,827,025 | 1.8 M to 1.8 M (+1.53 %) |
| Sep 03 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.64 | 36,494 | 643,754 | 1,799,430 | 1.8 M to 1.8 M (+2.07 %) |
| Sep 03 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 18.32 | 7,613 | 139,470 | 970,005 | 977.6 K to 970 K (-0.78 %) |
| Sep 03 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 17.62 | 17,387 | 306,359 | 977,618 | 995 K to 977.6 K (-1.75 %) |
| Aug 31 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.89 | 26,135 | 467,555 | 1,762,936 | 1.7 M to 1.8 M (+1.50 %) |
| Aug 31 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.79 | 36,359 | 646,827 | 1,736,801 | 1.7 M to 1.7 M (+2.14 %) |
| Aug 31 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.89 | 26,135 | 467,555 | 1,762,936 | 1.7 M to 1.8 M (+1.50 %) |
| Aug 31 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.79 | 36,359 | 646,827 | 1,736,801 | 1.7 M to 1.7 M (+2.14 %) |
| Aug 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 18.00 | 100 | 1,800 | 1,700,442 | 1.7 M to 1.7 M (+0.01 %) |
| Aug 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.96 | 11,024 | 197,991 | 1,700,342 | 1.7 M to 1.7 M (+0.65 %) |
| Aug 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.97 | 7,321 | 131,558 | 1,689,318 | 1.7 M to 1.7 M (+0.44 %) |
| Aug 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 18.00 | 100 | 1,800 | 1,700,442 | 1.7 M to 1.7 M (+0.01 %) |
| Aug 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.96 | 11,024 | 197,991 | 1,700,342 | 1.7 M to 1.7 M (+0.65 %) |
| Aug 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.97 | 7,321 | 131,558 | 1,689,318 | 1.7 M to 1.7 M (+0.44 %) |
| Aug 17 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.89 | 6,425 | 114,943 | 1,681,997 | 1.7 M to 1.7 M (+0.38 %) |
| Aug 17 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.49 | 37,993 | 664,498 | 1,675,572 | 1.6 M to 1.7 M (+2.32 %) |
| Aug 17 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.89 | 19,895 | 355,922 | 1,637,579 | 1.6 M to 1.6 M (+1.23 %) |
| Aug 17 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.89 | 6,425 | 114,943 | 1,681,997 | 1.7 M to 1.7 M (+0.38 %) |
| Aug 17 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.49 | 37,993 | 664,498 | 1,675,572 | 1.6 M to 1.7 M (+2.32 %) |
| Aug 17 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.89 | 19,895 | 355,922 | 1,637,579 | 1.6 M to 1.6 M (+1.23 %) |
| Aug 11 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 19.02 | 25,000 | 475,500 | 995,005 | 1 M to 995 K (-2.45 %) |
| Aug 03 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.99 | 732 | 13,169 | 1,617,684 | 1.6 M to 1.6 M (+0.05 %) |
| Aug 03 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.99 | 732 | 13,169 | 1,617,684 | 1.6 M to 1.6 M (+0.05 %) |
| Jul 30 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.99 | 4,105 | 73,849 | 1,616,952 | 1.6 M to 1.6 M (+0.25 %) |
| Jul 30 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.99 | 4,105 | 73,849 | 1,616,952 | 1.6 M to 1.6 M (+0.25 %) |
| Jul 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.99 | 3,834 | 68,974 | 1,612,847 | 1.6 M to 1.6 M (+0.24 %) |
| Jul 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.93 | 68,749 | 1,232,670 | 1,609,013 | 1.5 M to 1.6 M (+4.46 %) |
| Jul 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.99 | 3,834 | 68,974 | 1,612,847 | 1.6 M to 1.6 M (+0.24 %) |
| Jul 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 17.93 | 68,749 | 1,232,670 | 1,609,013 | 1.5 M to 1.6 M (+4.46 %) |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Option Exercise | M | 13.35 | 24,000 | 320,400 | 0 | |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Option Exercise | A | 20.37 | 16,806 | 342,338 | 16,806 | |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Option Exercise | A | 13.35 | 24,000 | 320,400 | 24,000 | |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Option Exercise | A | 13.35 | 24,000 | 320,400 | 24,000 | |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 18.00 | 193 | 3,474 | 1,540,264 | 1.5 M to 1.5 M (+0.01 %) |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | M | 13.35 | 24,000 | 320,400 | 44,000 | 20 K to 44 K (+120.00 %) |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Option Exercise | M | 13.35 | 24,000 | 320,400 | 0 | |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Option Exercise | A | 20.37 | 16,806 | 342,338 | 16,806 | |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Option Exercise | A | 13.35 | 24,000 | 320,400 | 24,000 | |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Option Exercise | A | 13.35 | 24,000 | 320,400 | 24,000 | |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | P | 18.00 | 193 | 3,474 | 1,540,264 | 1.5 M to 1.5 M (+0.01 %) |
| Jul 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | Director | Buy | M | 13.35 | 24,000 | 320,400 | 44,000 | 20 K to 44 K (+120.00 %) |
| Jun 17 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 21.79 | 19,400 | 422,726 | 1,045,005 | 1.1 M to 1 M (-1.82 %) |
| Jun 17 2020 | NGM | NGM BIOPHARMACEUTI ... | CHEN JIN-LONG | Chief Scientific Of ... | Sell | S | 21.15 | 5,600 | 118,440 | 1,064,405 | 1.1 M to 1.1 M (-0.52 %) |
| Jun 09 2020 | NGM | NGM BIOPHARMACEUTI ... | Ho Carole | Director | Option Exercise | A | 20.66 | 39,515 | 816,380 | 39,515 | |
| May 22 2020 | NGM | NGM BIOPHARMACEUTI ... | Hooper Suzanne Sawochka | Director | Option Exercise | A | 20.37 | 16,806 | 342,338 | 16,806 | |
| May 22 2020 | NGM | NGM BIOPHARMACEUTI ... | TICHENOR MCHENRY T | Director | Option Exercise | A | 20.37 | 16,806 | 342,338 | 16,806 | |
| May 22 2020 | NGM | NGM BIOPHARMACEUTI ... | SCHNELL DAVID | Director | Option Exercise | A | 20.37 | 16,806 | 342,338 | 16,806 | |
| May 22 2020 | NGM | NGM BIOPHARMACEUTI ... | LESCHLY MARK | Director | Option Exercise | A | 20.37 | 16,806 | 342,338 | 16,806 | |
| May 22 2020 | NGM | NGM BIOPHARMACEUTI ... | Guyer Shelly D | Director | Option Exercise | A | 20.37 | 16,806 | 342,338 | 16,806 | |
| May 22 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Option Exercise | A | 20.37 | 16,806 | 342,338 | 16,806 | |
| Apr 09 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 14.95 | 112,602 | 1,683,400 | 17,706,978 | 17.6 M to 17.7 M (+0.64 %) |
| Apr 09 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 14.95 | 112,602 | 1,683,400 | 17,896,978 | 17.8 M to 17.9 M (+0.63 %) |
| Apr 09 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 14.95 | 112,602 | 1,683,400 | 1,540,071 | 1.4 M to 1.5 M (+7.89 %) |
| Apr 09 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 14.95 | 112,602 | 1,683,400 | 1,540,071 | 1.4 M to 1.5 M (+7.89 %) |
| Apr 07 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 14.38 | 123,728 | 1,779,209 | 17,594,376 | 17.5 M to 17.6 M (+0.71 %) |
| Apr 07 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 12.41 | 14,587 | 181,025 | 17,470,648 | 17.5 M to 17.5 M (+0.08 %) |
| Apr 07 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 14.38 | 123,728 | 1,779,209 | 17,784,376 | 17.7 M to 17.8 M (+0.70 %) |
| Apr 07 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 12.41 | 14,587 | 181,025 | 17,660,648 | 17.6 M to 17.7 M (+0.08 %) |
| Apr 07 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 14.38 | 123,728 | 1,779,209 | 1,427,469 | 1.3 M to 1.4 M (+9.49 %) |
| Apr 07 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.41 | 14,587 | 181,025 | 1,303,741 | 1.3 M to 1.3 M (+1.13 %) |
| Apr 07 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 14.38 | 123,728 | 1,779,209 | 1,427,469 | 1.3 M to 1.4 M (+9.49 %) |
| Apr 07 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.41 | 14,587 | 181,025 | 1,303,741 | 1.3 M to 1.3 M (+1.13 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 12.40 | 14,850 | 184,140 | 17,456,061 | 17.4 M to 17.5 M (+0.09 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 12.26 | 118,067 | 1,447,501 | 17,441,211 | 17.3 M to 17.4 M (+0.68 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 12.53 | 118,067 | 1,479,380 | 17,323,144 | 17.2 M to 17.3 M (+0.69 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 12.40 | 14,850 | 184,140 | 17,646,061 | 17.6 M to 17.6 M (+0.08 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 12.26 | 118,067 | 1,447,501 | 17,631,211 | 17.5 M to 17.6 M (+0.67 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 12.53 | 118,067 | 1,479,380 | 17,513,144 | 17.4 M to 17.5 M (+0.68 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.40 | 14,850 | 184,140 | 1,289,154 | 1.3 M to 1.3 M (+1.17 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.26 | 118,067 | 1,447,501 | 1,274,304 | 1.2 M to 1.3 M (+10.21 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.53 | 118,067 | 1,479,380 | 1,156,237 | 1 M to 1.2 M (+11.37 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.40 | 14,850 | 184,140 | 1,289,154 | 1.3 M to 1.3 M (+1.17 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.26 | 118,067 | 1,447,501 | 1,274,304 | 1.2 M to 1.3 M (+10.21 %) |
| Apr 02 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.53 | 118,067 | 1,479,380 | 1,156,237 | 1 M to 1.2 M (+11.37 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.49 | 2,416 | 30,176 | 1,038,170 | 1 M to 1 M (+0.23 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.22 | 128,377 | 1,568,767 | 1,035,754 | 907.4 K to 1 M (+14.15 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 11.63 | 170,387 | 1,981,601 | 907,377 | 737 K to 907.4 K (+23.12 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 12.49 | 2,416 | 30,176 | 17,205,077 | 17.2 M to 17.2 M (+0.01 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 12.22 | 128,377 | 1,568,767 | 17,202,661 | 17.1 M to 17.2 M (+0.75 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 11.63 | 170,387 | 1,981,601 | 17,074,284 | 16.9 M to 17.1 M (+1.01 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 12.49 | 2,416 | 30,176 | 17,395,077 | 17.4 M to 17.4 M (+0.01 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 12.22 | 128,377 | 1,568,767 | 17,392,661 | 17.3 M to 17.4 M (+0.74 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 12.49 | 2,416 | 30,176 | 17,205,077 | 17.2 M to 17.2 M (+0.01 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 11.63 | 170,387 | 1,981,601 | 17,264,284 | 17.1 M to 17.3 M (+1.00 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 12.22 | 128,377 | 1,568,767 | 17,202,661 | 17.1 M to 17.2 M (+0.75 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 11.63 | 170,387 | 1,981,601 | 17,074,284 | 16.9 M to 17.1 M (+1.01 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.49 | 2,416 | 30,176 | 1,038,170 | 1 M to 1 M (+0.23 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.22 | 128,377 | 1,568,767 | 1,035,754 | 907.4 K to 1 M (+14.15 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 11.63 | 170,387 | 1,981,601 | 907,377 | 737 K to 907.4 K (+23.12 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 12.49 | 2,416 | 30,176 | 17,395,077 | 17.4 M to 17.4 M (+0.01 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 12.22 | 128,377 | 1,568,767 | 17,392,661 | 17.3 M to 17.4 M (+0.74 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 11.63 | 170,387 | 1,981,601 | 17,264,284 | 17.1 M to 17.3 M (+1.00 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.49 | 2,416 | 30,176 | 1,038,170 | 1 M to 1 M (+0.23 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 12.22 | 128,377 | 1,568,767 | 1,035,754 | 907.4 K to 1 M (+14.15 %) |
| Mar 25 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 11.63 | 170,387 | 1,981,601 | 907,377 | 737 K to 907.4 K (+23.12 %) |
| Mar 23 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 11.77 | 143,082 | 1,684,075 | 16,903,897 | 16.8 M to 16.9 M (+0.85 %) |
| Mar 23 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 11.59 | 148,464 | 1,720,698 | 16,760,815 | 16.6 M to 16.8 M (+0.89 %) |
| Mar 23 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 11.77 | 143,082 | 1,684,075 | 17,093,897 | 17 M to 17.1 M (+0.84 %) |
| Mar 23 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 11.59 | 148,464 | 1,720,698 | 16,950,815 | 16.8 M to 17 M (+0.88 %) |
| Mar 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 11.77 | 143,082 | 1,684,075 | 736,990 | 593.9 K to 737 K (+24.09 %) |
| Mar 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 11.59 | 148,464 | 1,720,698 | 593,908 | 445.4 K to 593.9 K (+33.33 %) |
| Mar 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 11.77 | 143,082 | 1,684,075 | 736,990 | 593.9 K to 737 K (+24.09 %) |
| Mar 23 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 11.59 | 148,464 | 1,720,698 | 593,908 | 445.4 K to 593.9 K (+33.33 %) |
| Mar 06 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 18.00 | 8,307 | 149,526 | 445,444 | 437.1 K to 445.4 K (+1.90 %) |
| Mar 06 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 18.00 | 8,307 | 149,526 | 445,444 | 437.1 K to 445.4 K (+1.90 %) |
| Mar 06 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 18.00 | 8,307 | 149,526 | 16,612,351 | 16.6 M to 16.6 M (+0.05 %) |
| Mar 06 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 18.00 | 8,307 | 149,526 | 16,802,351 | 16.8 M to 16.8 M (+0.05 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.96 | 9,986 | 179,349 | 437,137 | 427.2 K to 437.1 K (+2.34 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.99 | 38,758 | 697,256 | 427,151 | 388.4 K to 427.2 K (+9.98 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.90 | 14,124 | 252,820 | 388,393 | 374.3 K to 388.4 K (+3.77 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.96 | 9,986 | 179,349 | 437,137 | 427.2 K to 437.1 K (+2.34 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.99 | 38,758 | 697,256 | 427,151 | 388.4 K to 427.2 K (+9.98 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.90 | 14,124 | 252,820 | 388,393 | 374.3 K to 388.4 K (+3.77 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 17.96 | 9,986 | 179,349 | 16,604,044 | 16.6 M to 16.6 M (+0.06 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 17.99 | 38,758 | 697,256 | 16,594,058 | 16.6 M to 16.6 M (+0.23 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 17.90 | 14,124 | 252,820 | 16,555,300 | 16.5 M to 16.6 M (+0.09 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 17.96 | 9,986 | 179,349 | 16,794,044 | 16.8 M to 16.8 M (+0.06 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 17.99 | 38,758 | 697,256 | 16,784,058 | 16.7 M to 16.8 M (+0.23 %) |
| Mar 04 2020 | NGM | NGM BIOPHARMACEUTI ... | GOEDDEL DAVID V | Director | Buy | P | 17.90 | 14,124 | 252,820 | 16,745,300 | 16.7 M to 16.7 M (+0.08 %) |
| Feb 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.91 | 37,800 | 676,998 | 374,269 | 336.5 K to 374.3 K (+11.23 %) |
| Feb 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.91 | 33,896 | 607,077 | 336,469 | 302.6 K to 336.5 K (+11.20 %) |
| Feb 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 18.00 | 3,751 | 67,518 | 302,573 | 298.8 K to 302.6 K (+1.26 %) |
| Feb 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.91 | 37,800 | 676,998 | 374,269 | 336.5 K to 374.3 K (+11.23 %) |
| Feb 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 17.91 | 33,896 | 607,077 | 336,469 | 302.6 K to 336.5 K (+11.20 %) |
| Feb 28 2020 | NGM | NGM BIOPHARMACEUTI ... | COLUMN GROUP L P | 10% Owner | Buy | P | 18.00 | 3,751 | 67,518 | 302,573 | 298.8 K to 302.6 K (+1.26 %) |
| Feb 28 2020 | NGM | NGM BIOPHARMACEUTI ... | Svennilson Peter | Director | Buy | P | 17.91 | 37,800 | 676,998 | 16,541,176 | 16.5 M to 16.5 M (+0.23 %) |